Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Windy City Times 2022-08-31
DOWNLOAD ISSUE
Donate

Sponsor
Sponsor

  WINDY CITY TIMES

PrEP options likely to change following Truvada patent expiration
by Matt Simonette
2021-03-04

This article shared 2634 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email


Among the myriad challenges facing HIV/AIDS advocates and healthcare providers has been increasing use of pre-exposure prophylaxis, or PrEP, among persons at risk for HIV transmission. A PrEP intervention, which usually consists of taking the oral medication Truvada, has been shown to decrease the risk of transmission by more than 90 percent.

Truvada was approved for PrEP use by the Food and Drug Administration in 2012 and, since then, has been widely prescribed by physicians to help at-risk patients prevent HIV transmission (it was earlier used to treat persons living with HIV). But Truvada's patent expiration in 2020 means both generic options for consumers are forthcoming and that a competing drug, Descovy, by the same manufacturer, is already on the market.

Some advocates are looking forward to having lower-cost options available. AIDS Foundation of Chicago (AFC) Senior Director of Prevention Advocacy and Gay Men's Health Jim Pickett suspects that "lower drug costs will lower the cost of access and alleviate some pressure on the system."

He added, "With PrEP, the costs are not just about the drug. There are costs affiliated with seeing your doctor, having blood work done, being tested for HIV and STI's. It's important to remember that services that come along with PrEP are part of the program—PrEP isn't just a prescription. If our system can spend less on the drug, there's arguably more money to cover those other things which can be prohibitive for people."

The cost of Truvada—which is a combination of the drugs known generically as tenofovir disoproxil fumarate and emtricitabine—has indeed been a key deterrent to widespread PrEP implementation. A month's supply of the medication is often $1,500-2,000. Nevertheless, many insurers cover Truvada in their formularies, and the medication's manufacturer, Foster City, California-based Gilead Sciences, provides consumer assistance for monthly co-payments their plans require.

Various public health agencies have also made PrEP access a central component to long-term strategies that eliminate new HIV transmissions, such as the Getting to Zero initiative launched in Illinois in late 2018. The federal government announced a similar program with PrEP interventions playing a central role in early 2019.

Nevertheless, PrEP adoption numbers remain far behind where advocates and providers want to see them. Getting the message about PrEP to white gay men has been a relatively minimal challenge, but communicating that same message to diverse audiences at risk, such as transgender women or young Black men, remains problematic. Usage in the southern United States, where a large number of new HIV transmissions take place, is also low.

In late 2019, Gilead announced it would donate a five-year supply of Truvada to 200,000 people. Their Truvada patent expired in late 2020. The company reached an exclusivity agreement for six months Israeli pharmaceutical manufacturer Teva for a generic version of tenofovir disoproxil fumarate and emtricitabine. Starting in spring 2021, Teva's exclusivity window expires and any manufacturer can produce a generic version of tenofovir disoproxil fumarate and emtricitabine.

Gilead still intends to remain a player in manufacturing and distributing medications for PrEP, however. In 2019, it received approval for use of Descovy as a PrEP intervention and has aggressively marketed the new drug as a replacement for Truvada. Google users who search "Truvada generic" will likely spot an advertisement for Descovy toward the top of their results.

Among the advantages of Descovy, according to Gilead, are reduced chances of complications to kidneys or bone density, which are stated side-effects to Truvada. But Descovy shares the same high cost as Truvada, about $16,600-20,000 a year, according to aidsmap.com .

Many advocates and providers say that there is no need for a "mass exodus" from Truvada to Descovy for PrEP users, Pickett said.

"In terms of prescribing for PrEP, the vast majority of people using Truvada for PrEP have absolutely zero clinical need to switch over to Descovy," he added. "The only clinical reason to switch would be if you have some underlying kidney or bone disease, or if Truvada is giving your kidneys a hard time."

Gilead could not provide a spokesperson to comment on Descovy by this article's deadline. Shortly after Descovy was approved for PrEP in October 2019, Daniel O'Day, Gilead's chairman and CEO, said the new medication nevertheless "provides a new HIV prevention option that matches Truvada's high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time."

Prior to her appointment as director of the Centers for Disease Control and Prevention, Rochelle Walensky, MD, was lead author on a March 2020 Annals of Internal Medicine study which concluded that mitigating for Truvada's side-effects with a new medication was outweighed by the benefits of a lower-cost generic substitute for Truvada. Other researchers also have expressed concern that Descovy has not been tested on as diverse a population as Truvada has been.

"We already are seeing insurance companies pointing people to the generic alternative—when you are prescribed PrEP, the insurance company might cover the generic form of Truvada," Pickett said. "They may or may not be inclined to cover Truvada itself. We are also seeing insurance companies put in utilization-management for Descovy, so if you are prescribed Descovy, the doctor has to show clinical need."

Gilead has also been involved in extensive litigation with the federal government regarding the PrEP-related patents. The CDC sued the company in 2019, maintaining that it had not been properly compensated for federal researchers' contributions to Truvada and Descovy's development. In January 2021, a federal judge rejected the Justice Department's motion to dismiss Gilead's counterclaims that the federal government had been in breach of key contracts, so the litigation will continue.

But for now, a key challenge for stakeholders remains getting the costs under control. Using PrEP represents a collective commitment of time and money for patients, providers and insurers.

In the years ahead, the PrEP landscape will likely change even further. An injectable version of the intervention has proven to be as effective as oral applications. In such a scenario, the medication cabotegravir could be injected and offer two months' worth of protection for patients who don't wish to take a pill every day.

Pickett said he didn't foresee injectable PrEP completely replacing pills however, noting that compliance challenges might only shift for some consumers. While the injection saves the patient from the responsibility of taking a pill, they'd still need a bimonthly appointment to receive it.

"I don't see it as replacing [oral medication]—I see it as being additive," Pickett said. "I see it drawing in people who struggle with PrEP because it is a pill, or aren't interested because it's a pill. Overall, if we do it right and create support systems that make it easy for people to get their shots—imagine being able to do it at Walgreens—I'll be super-excited about it. It means people having more options and more protection."


This article shared 2634 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email

  ARTICLES YOU MIGHT LIKE

Gay News

AIDS Foundation Chicago holding Women's Connection Summit of Hope on Oct. 6 2022-09-27
-- From a press release - AIDS Foundation Chicago (AFC) is hosting a Women Connection Summit of Hope in partnership with the Illinois Department of Corrections (IDOC) to address the needs of cis and transgender women who have been recently released from ...


Gay News

AIDS Foundation Chicago hosts two-day event about unique challenges facing elders living with HIV/AIDS 2022-09-24
- AIDS Foundation Chicago hosted a two-part educational webinar about the complex needs of elders living with HIV/AIDS Sept. 22-23, where experts discussed how to better serve patients through healthcare, policies ...


Gay News

National AIDS Memorial releases 'The Black Community & AIDS' 2022-09-23
- The National AIDS Memorial has released its latest mini-documentary, "The Black Community & AIDS," the seventh film in its oral history project. "The Black Community & AIDS" chronicles the personal stories of nearly two dozen survivors ...


Gay News

DoJ secures agreement resolving HIV-discrimination suit in Indiana 2022-09-19
- The Justice Department filed a proposed consent decree with the U.S. District Court for the Southern District of Indiana to resolve its lawsuit against the town of Clarksville, Indiana, for violating Title I of the Americans ...


Gay News

AIDS organization honors actors Farrell, Ralph and Theron 2022-09-19
- On Sept. 15, The Elizabeth Taylor AIDS Foundation (ETAF) honored actors Sheryl Lee Ralph, Charlize Theron and Colin Farrell with the Elizabeth Taylor Commitment to End AIDS Award at The Elizabeth Taylor Ball to End AIDS ...


Gay News

Illinois HIV Care Connect introduces its HIV and Aging Campaign 2022-09-15
- In advance of National HIV/AIDS and Aging Awareness Day on Sept. 18, Illinois HIV Care Connect has introduced its HIV and Aging Campaign. Persons aged 50 and older make up nearly half of persons living with ...


Gay News

Texas judge: Mandated PrEP coverage violates religious freedom 2022-09-08
- On Sept. 7, a federal judge in Texas (U.S. District Judge Reed O'Connor) ruled that the government cannot force a Christian-owned company to cover HIV preventative medication (HIV PrEP) because it violates their religious freedom under ...


Gay News

Getting to Zero, AFC award $200K to help end the HIV epidemic in Illinois 2022-09-07
- Getting to Zero Illinois (GTZ-IL) and AIDS Foundation Chicago (AFC) recently awarded $200,000 to community-based organizations implementing strategies to end the HIV/AIDS epidemic by 2030. According to a press release ...


Gay News

Philadelphia AIDS and housing activist Michael Hinson Jr. dies at 55 2022-09-04
- Michael Hinson Jr.—a longtime AIDS and housing activist, and leader in Philadelphia's Black LGBTQ+ community—died Aug. 27 of an undisclosed cause at age 55, The Philadelphia Inquirer reported. An obituary in the Philadelphia Gay News stated ...


Gay News

Howard Brown president/CEO reflects on COVID's impact 2022-08-31
- According to Howard Brown Health President and CEO David Munar, the early days of the COVID-19 pandemic seemed eerily similar to the AIDS crisis of the '80s. "We saw all the same patterns at the dawning ...


Gay News

NATIONAL Gay judge, brewery threatened, Victory Fund, AIDS Quilt 2022-08-28
- New York's highest court has designated Associate Judge Anthony Cannataro to serve as acting chief judge after Janet DiFiore steps down, Gay City News reported. Cannataro, the former administrative judge of New York City's civil court, ...


Gay News

HHS Secretary Becerra announces more than $20 million in funding to end HIV epidemic 2022-08-23
-- From a press release - Today, at the National Ryan White Conference on HIV Care and Treatment, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra announced more than $20 million in funding to expand HIV prevention, testing, and ...


Gay News

Kinsey Institute exhibiting iconic Tom Fox HIV/AIDS photo series 2022-08-05
- An exhibition of 60 iconic photographs documenting Indiana University alumnus Tom Fox's battle with AIDS in the late 1980s will hang in the Grand Hall of Maxwell Hall on the Indiana University-Bloomington campus. "Wild Horse Running: ...


Gay News

Black AIDS Institute seeks president/CEO 2022-07-27
- The Black AIDS Institute (BAI) has partnered with Coleman Lew Canny Bowen, a retained executive search firm, to conduct a search for a president/CEO. This position reports directly to the board of directors and leads a ...


Gay News

Registration for the 31st Annual AIDS Run & Walk only $24 for 24 hours on July 24 2022-07-23
-- From a press release - (Chicago, IL) AIDS Foundation Chicago (AFC) announces the return of its popular $24 for 24 promotion on July 24 for discounted registration for the 31st annual AIDS Run & Walk Chicago (ARWC) taking place Oct. 2 ...


 



Copyright © 2022 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 
 

TRENDINGBREAKINGPHOTOS







Sponsor


 

Sponsor


Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam     
Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.